Item 9 Labs Strengthens Executive Team
SCOTTSDALE, Ariz., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Item 9 Labs Corp. (OTC: INLB) (Item 9 Labs or the Company), a leading developer and manufacturer of innovative cannabis products and proprietary delivery platforms, today announced Chris Wolven is joining the executive team as Chief Operating Officer.
Wolven previously served as Brand Chef at Fox Restaurant Concepts, a culinary powerhouse renowned for its boutique brands and thoughtfully curated dining experiences. The group has an impressive lineup of more than 50 restaurant locations throughout the nation.
“We are excited to have Chris join our team. His passion for quality ingredients, a high-level of service, and superior customer experience compliments our mission and vision,” stated Sara Gullickson, CEO of Item 9 Labs. “Chris has opened establishments throughout the country with a gold standard for excellence, which is exactly what we need as we expand our operations.”
Wolven was responsible for operations and food development for seven of the 15 brands under Fox Restaurant Concepts, spanning ten locations with over 1,000 employees. He oversaw creative development, financial planning, the building and implementation of systems, as well as operational wellbeing. Wolven’s region brought in over $50 million in annual revenue.
“It’s an absolute honor to be working with some of the industry’s top professionals at an organization dedicated to crafting distinctive and progressive cannabis brands,” said Chris Wolven, Chief Operating Officer.
Item 9 Labs is an all-encompassing cannabis enterprise. It will be operating as licensed dispensaries, cultivation, and manufacturing facilities in six to ten U.S. markets by the end of 2019.
The Company currently operates an indoor cultivation facility zoned on 50 acres in Arizona and has joint ventures in medical cannabis cultivation and processing facility Strive Wellness of Nevada, LLC, and dispensary Strive Life North Dakota.
For information visit Item9LabsCorp.com.
About Item 9 Labs Corp.:
Item 9 Labs Corp. (OTC: INLB) creates comfortable cannabis health solutions for the modern consumer by developing innovative products and proprietary delivery platforms. The Company is focused on the development of technology and products that administer high-quality medical marijuana through a novel intra-nasal delivery system to deliver significant health benefits. The Company is headquartered in Southern Arizona where it owns and operates 50 acres, one of the largest properties in the U.S. zoned to grow and cultivate the medical marijuana flower. Item 9 has a proven track record of providing consumers with high-quality medical marijuana flower and products focused on organic, cost-effective solutions for whole body health. By combining high-quality, medical-grade product with the Company’s proprietary nasal mucus-membrane delivery system, Item 9 plans to produce the industry’s first market medicated nasal delivery device that administers specific cannabinoid dosing to meet the growing demand of today’s modern cannabis consumer. For more information, visit us online at www.Item9labscorp.com and www.Item9labs.com.
Forward-Looking Statement: This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, proposed transactions that are not legally binding obligations of the company and the ability to manage and continue growth. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Media Contact: Neko Catanzaro Proven Media Neko@provenmediaservices.com (401) 484-4980
Investor Contact: Jeffrey Rassas Item 9 Labs Corp. Jeffrey@item9labs.com (602) 463-4246